CEO Greg Duncan Talks Virios Therapeutics (VIRI)

The CEO and Chairman of the Board of Directors of Virios Therapeutics (VIRI), Greg Duncan, says that the clinical-stage biotechnology company is focused on novel, dual mechanism antiviral therapies to treat chronic debilitating diseases like fibromyalgia. The stock began trading on the Nasdaq in December 2020.

The Watch List

20 Apr 2021

ON AIR
7:00 am
Market Overtime
replay

Get Market Minute

Daily insights for every investor

FOLLOW US

CEO Greg Duncan Talks Virios Therapeutics (VIRI)

The CEO and Chairman of the Board of Directors of Virios Therapeutics (VIRI), Greg Duncan, says that the clinical-stage biotechnology company is focused on novel, dual mechanism antiviral therapies to treat chronic debilitating diseases like fibromyalgia. The stock began trading on the Nasdaq in December 2020.

The Watch List

20 Apr 2021

ON AIR
7:00 am
Market Overtime
replay

Get Market Minute

Daily insights for every investor

FOLLOW US